Biotest AG BIOTEST PREF SHS
Biotest AG BIOTEST PREF SHS/ DE0005227235 /
0N70
|
08/11/2024 15:10:33
|
Diferencia
-1.95
|
Volumen |
Bid- |
Ask- |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
25.75EUR
|
-7.04%
|
100,000
Volumen de negocios: 2.58 millones |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
2.43 mil millonesEUR |
0.05% |
12.81 |
Descripción de negocio
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
Consejo de gestión & Consejo de supervisión
| CEO |
| Peter Janssen |
| Consejo de gestión |
| Ainhoa Mendizabal Zubiaga, Dr. Jörg Schüttrumpf, Dr. Michael Ramroth, Dr. Georg Floß |
| Consejo de supervisión |
| Dr. Bernhard Ehmer, David Bell, Uta Kemmerich-Keil, Jürgen Heilmann, Dirk Schuck, Raimon Grifols Roura |
Datos de la empresa
| Nombre: |
Biotest AG |
| Dirección: |
Landsteinerstraße 5,D-63303 Dreieich |
| Teléfono: |
+49-6103-801-0 |
| Fax: |
+49-6103-801-150 |
| E-mail: |
mail@biotest.de
|
| Internet: |
www.biotest.de |
| Industria: |
Healthcare |
| Sector: |
Medical Products |
| Subsector: |
Advanced Medical Devices |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
14/10/1987 |
Relación con inversores
| Nombre: |
Dr. Monika Buttkereit |
| IR teléfono: |
+49-6103-801-4406 |
| IR-fax: |
+49-6103-801-347 |
| IR e-mail: |
investor_relations@biotest.de
|
